U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06882122) titled 'Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine' on March 11.
Brief Summary: The investigators aim to assess and compare neurophysiological and biochemical changes induced by a 3-month treatment with atogepant (60 mg daily) in patients with high-frequency episodic migraine (8-14 monthly migraine days). Evaluations will include neurophysiological assessments (High-Density EEG, nociceptive reflexes, and visual evoked potentials) and biomolecular profiling (gene expression of endocannabinoid catabolizing enzymes, CGRP and PACAP plasma levels, and headache-specific microRNAs). Outputs will contribute to de...